Leona Plum

List of Publications by Year
in descending order

31 papers	4,548 citations	304743 22 h-index	434195 31 g-index
31 all docs	31 docs citations	31 times ranked	6443 citing authors

#	Article	IF	Citations
1	Pharmacokinetic and Glucodynamic Responses of Ultra Rapid Lispro vs Lispro Across a Clinically Relevant Range of Subcutaneous Doses in Healthy Subjects. Clinical Therapeutics, 2020, 42, 1762-1777.e4.	2.5	12
2	Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 179-188.	11.4	116
3	The Effect of Food Intake on the Pharmacokinetics of Oral Basal Insulin: A Randomised Crossover Trial in Healthy Male Subjects. Clinical Pharmacokinetics, 2019, 58, 1497-1504.	3.5	23
4	Better glycaemic control with BioChaperone glargine lispro coâ€formulation than with insulin lispro Mix25 or separate glargine and lispro administrations after a test meal in people with type 2 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 1570-1575.	4.4	5
5	Injecting without pressing a button: An exploratory study of a shieldâ€triggered injection mechanism. Diabetes, Obesity and Metabolism, 2018, 20, 1140-1147.	4.4	2
6	Sequential Treatment Escalation with Dapagliflozin and Saxagliptin Improves Beta Cell Function in Type 2 Diabetic Patients on Previous Metformin Treatment: An Exploratory Mechanistic Study. Hormone and Metabolic Research, 2018, 50, 403-407.	1.5	8
7	Effects on Î±â€•and Î²â€cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving metformin: <scp>A</scp>n exploratory mechanistic study. Diabetes, Obesity and Metabolism, 2017, 19, 489-495.	4.4	16
8	Hypoglycemia Risk Related to Double Dose Is Markedly Reduced with Basal Insulin Peglispro Versus Insulin Glargine in Patients with Type 2 Diabetes Mellitus in a Randomized Trial: IMAGINE 8. Diabetes Technology and Therapeutics, 2017, 19, 463-470.	4.4	4
9	Euglycaemic glucose clamp: what it can and cannot do, and how to do it. Diabetes, Obesity and Metabolism, 2016, 18, 962-972.	4.4	67
10	Pharmacological Intervention in Type 2 Diabetes Mellitus - A Pathophysiologically Reasoned Approach?. Current Diabetes Reviews, 2016, 12, 429-439.	1.3	4
11	Oral Insulin Reloaded. Journal of Diabetes Science and Technology, 2014, 8, 458-465.	2.2	59
12	Blunted Refeeding Response and Increased Locomotor Activity in Mice Lacking FoxO1 in Synapsin-<i>Cre</i>â€"Expressing Neurons. Diabetes, 2013, 62, 3373-3383.	0.6	21
13	Validation of a Novel Method for Determining the Renal Threshold for Glucose Excretion in Untreated and Canagliflozin-treated Subjects With Type 2 Diabetes Mellitus. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E867-E871.	3.6	77
14	FoxO1 Target Gpr17 Activates AgRP Neurons to Regulate Food Intake. Cell, 2012, 149, 1314-1326.	28.9	164
15	A guide to analysis of mouse energy metabolism. Nature Methods, 2012, 9, 57-63.	19.0	655
16	InsR/FoxO1 Signaling Curtails Hypothalamic POMC Neuron Number. PLoS ONE, 2012, 7, e31487.	2.5	16
17	Comparison of Glucostatic Parameters After Hypocaloric Diet or Bariatric Surgery and Equivalent Weight Loss. Obesity, 2011, 19, 2149-2157.	3.0	67
18	Divergent Regulation of Energy Expenditure and Hepatic Glucose Production by Insulin Receptor in Agouti-Related Protein and POMC Neurons. Diabetes, 2010, 59, 337-346.	0.6	130

#	Article	IF	Citations
19	Myeloid Cell-Restricted Insulin Receptor Deficiency Protects Against Obesity-Induced Inflammation and Systemic Insulin Resistance. PLoS Genetics, 2010, 6, e1000938.	3.5	92
20	The obesity susceptibility gene Cpe links FoxO1 signaling in hypothalamic pro-opiomelanocortin neurons with regulation of food intake. Nature Medicine, 2009, 15, 1195-1201.	30.7	150
21	Insulin Action in AgRP-Expressing Neurons Is Required for Suppression of Hepatic Glucose Production. Cell Metabolism, 2007, 5, 438-449.	16.2	579
22	Enhanced Leptin-Stimulated Pi3k Activation in the CNS Promotes White Adipose Tissue Transdifferentiation. Cell Metabolism, 2007, 6, 431-445.	16.2	121
23	Central insulin action in energy and glucose homeostasis. Journal of Clinical Investigation, 2006, 116, 1761-1766.	8.2	352
24	gp130 signaling in proopiomelanocortin neurons mediates the acute anorectic response to centrally applied ciliary neurotrophic factor. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 10707-10712.	7.1	52
25	Enhanced PIP3 signaling in POMC neurons causes KATP channel activation and leads to diet-sensitive obesity. Journal of Clinical Investigation, 2006, 116, 1886-1901.	8.2	281
26	Agouti-related peptideâ€“expressing neurons are mandatory for feeding. Nature Neuroscience, 2005, 8, 1289-1291.	14.8	663
27	Peripheral Hyperinsulinemia Promotes Tau Phosphorylation In Vivo. Diabetes, 2005, 54, 3343-3348.	0.6	131
28	Single copy shRNA configuration for ubiquitous gene knockdown in mice. Nucleic Acids Research, 2005, 33, e67-e67.	14.5	101
29	The role of insulin receptor signaling in the brain. Trends in Endocrinology and Metabolism, 2005, 16, 59-65.	7.1	512
30	Diet-dependent obesity and hypercholesterolemia in the New Zealand obese mouse: identification of a quantitative trait locus for elevated serum cholesterol on the distal mouse chromosome 5. Biochemical and Biophysical Research Communications, 2003, 304, 812-817.	2.1	33
31	Effect of Hyperinsulinemia and Type 2 Diabetes-Like Hyperglycemia on Expression of Hepatic Cytochrome P450 and GlutathioneS-Transferase Isoforms in a New Zealand Obese-Derived Mouse Backcross Population. Journal of Pharmacology and Experimental Therapeutics, 2002, 302, 442-450.	2.5	35